CA2486697C — 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Assigned to Novartis AG · Expires 2009-01-06 · 17y expired
What this patent protects
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3'-~(2Z)-~1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene~hydrazino~-2'-hydroxy-~1,1'-biphenyl~-3-carboxylic acid.
USPTO Abstract
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3'-~(2Z)-~1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene~hydrazino~-2'-hydroxy-~1,1'-biphenyl~-3-carboxylic acid.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.